Why Evercell Bio chose VIPS: a new workflow for hiPSC in cell therapy

Philip D. Manos, Founder and President of EverCell Bio, Natick, Massachusetts, USA “Our mission is to accelerate the implementation of human and disease-specific stem cell technologies for drug discovery and personalized medicine” EverCell Bio is a single-source provider of customized services for the application of stem cell technology in cell therapy. EverCell offers human cell-modelling …

Read more Why Evercell Bio chose VIPS: a new workflow for hiPSC in cell therapy

Solentim Appoints New Non-Executive Director

Solentim are pleased to announce the appointment of Dr Julian Burke as a non-executive Director. A former lecturer in Biochemistry at the University of Sussex, UK, Dr Burke has over 25 years’ experience of executive leadership positions in life science companies. He was Chief Scientific Officer for Genetix Group PLC from 2000 – 2010 until …

Read more Solentim Appoints New Non-Executive Director

Clonality assurance and the rise of therapeutic monoclonal antibody development

Monoclonal antibodies – a recent history Over three decades ago, in 1986, the first monoclonal antibody (mAb) treatment was approved by the United States Food and Drug Administration (US FDA)[1]. Since then, techniques and technologies to identify, engineer and harness mAbs have advanced and therapeutic antibodies have become the primary focus for many drug developers. …

Read more Clonality assurance and the rise of therapeutic monoclonal antibody development

Is it time for a new standard for the culture of iPSCs?

For those delivering advanced therapy medicinal products, the question of assessing and managing cell population heterogeneity presents an ongoing challenge. Solentim and EverCell Bio addressed this topic at a recent webinar during which they discussed the use of induced pluripotent stem cells (iPSCs) and sharing data from EverCell Bio’s iPSC lines when moving into the clinic. …

Read more Is it time for a new standard for the culture of iPSCs?

Advances in cell line development at BPI Europe Virtual

Mark Stockdale, Amalgamator of Business and Biology at Solentim, discusses his key takeaways from this year’s BPI Europe Virtual. He shares his experiences of attending virtual conferences, the pros and cons of virtual events and how organisers need to improve. Entering the world of virtual events posed new challenges for delegates and speakers alike, but …

Read more Advances in cell line development at BPI Europe Virtual

WEBINAR | Establishing New Standards in Efficient Single Cell Cloning of hiPSCs

Tuesday, September 22, 2020 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central) 60 min Drug discovery, diagnostic, and therapeutic efforts are increasingly using human-induced pluripotent stem cells (hiPSCs) and related technologies. However, the inability to robustly manipulate hiPSCs as single cells has remained a significant biological and technical hurdle. Current techniques …

Read more WEBINAR | Establishing New Standards in Efficient Single Cell Cloning of hiPSCs